Snapshot from Sep 17, 2026 at 07:00 UTC. For live data and tracking: View Live
Business Settlement Agreement

Ascendis BioMarin YUVIWEL Settlement License

Analysis based on 6 articles · First reported Aug 31, 2026 · Last updated Aug 31, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The settlement removes litigation overhang and secures Ascendis' ability to commercialize YUVIWEL globally, likely boosting investor confidence and supporting Ascendis' revenue growth targets. BioMarin gains a steady royalty stream without further legal costs, positively impacting its financial outlook.

Biopharmaceuticals

Ascendis Pharma A/S and BioMarin Pharmaceutical Inc. have entered into a binding term sheet for a global settlement and license agreement resolving all litigation and disputes related to YUVIWEL (navepegritide). Under the terms, BioMarin grants Ascendis a non-exclusive, worldwide, royalty-bearing license to continue researching, developing, manufacturing, and commercializing navepegritide-related products without restriction. BioMarin also waives certain regulatory rights and exclusivities, dismisses all proceedings, and provides a covenant not to sue. In exchange, Ascendis dismisses all proceedings against BioMarin and agrees to pay royalties of 20% in the United States and 18% in the European Union, South Korea, and Brazil on net sales of navepegritide-related products from first commercial sale through May 20, 2030. The settlement removes legal uncertainty and allows Ascendis to focus on the commercial success of YUVIWEL, which was approved by the FDA in February 2026 for achondroplasia. Ascendis expects to generate over €500 million in operating cash flow in 2026 and believes it can achieve €5 billion in revenue by 2030.

100 Ascendis Pharma entered binding term sheet BioMarin Pharmaceutical
90 Ascendis Pharma agreed to pay royalties BioMarin Pharmaceutical
80 BioMarin Pharmaceutical waived regulatory rights Ascendis Pharma
80 Ascendis Pharma dismissed proceedings BioMarin Pharmaceutical
stock
Ascendis is the primary beneficiary, securing a global license and resolving litigation, enabling continued commercialization of YUVIWEL and supporting its revenue targets.
Importance 100.0 Sentiment 80.0
stock
BioMarin grants a license and receives royalties, ending costly litigation and providing a new revenue stream, though it loses some exclusivity rights.
Importance 90.0 Sentiment 60.0
govactor
The FDA approved YUVIWEL in February 2026, a prerequisite for the product's commercialization and the settlement's relevance.
Importance 30.0 Sentiment 40.0
cnt
The US is a key market for YUVIWEL, with rapid uptake noted; the settlement secures Ascendis' ability to sell there.
Importance 30.0 Sentiment 50.0
govactor
The EMA is reviewing Ascendis' marketing application for YUVIWEL, with a decision expected in Q4 2026, which could expand the market.
Importance 25.0 Sentiment 40.0
per
As CEO of Ascendis, Jan Mikkelsen is the public spokesperson for the settlement, reinforcing leadership confidence in YUVIWEL's market potential.
Importance 20.0 Sentiment 50.0
alliance
The EU is a major market where Ascendis will pay 18% royalties, and where regulatory approval is pending.
Importance 20.0 Sentiment 40.0
cnt
South Korea is one of the countries where Ascendis will pay royalties, indicating a planned commercial presence.
Importance 10.0 Sentiment 30.0
cnt
Brazil is another royalty-paying market, reflecting the global scope of the settlement.
Importance 10.0 Sentiment 30.0
cnt
Denmark is Ascendis' headquarters, but the settlement has no direct impact on the country itself.
Importance 5.0 Sentiment 20.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.